Immunogens comprising human immunodeficiency virus V1/V2 polypeptides

Inventors: Barton F. Haynes (Durham, NC); Huaxin Liao (Durham, NC); Jerome Kim (Fort Detrick, MD); Nelson Michael (Fort Detrick, MD); Susan B. Zolla-Pazner (New York, NY)

Assignees: DUKE UNIVERSITY; U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND; NEW YORK UNIVERSITY

C07K14/005 A61K39/12 A61K39/21 C07K14/162 C07K16/1063 C07K2317/34 C07K2317/55 C07K2317/76 C07K2317/92 C12N2710/24043 C12N2740/16034 C12N2740/16122 C12N2740/16134

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 9,988,424
App. No.: 14/363,131
Granted: Jun 5, 2018
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The invention is generally directed to V1V2 immunogens.

Claims (20)

1. A V1V2 polypeptide, wherein the polypeptide is AE.A244 V1/V2 (SEQ ID NO: 184), AE.A244 V1/V2tag (SEQ ID NO: 196), A.Q23V1/V2 (SEQ ID NO: 183), or A.Q23V1/V2tag (SEQ ID NO: 195).

2. A composition comprising any one of the polypeptides of claim 1 and a carrier.

3. The composition according to claim 2 further comprising an adjuvant.

4. A V1V2 polypeptide, wherein the polypeptide consists essentially of peptide AE.A244 V1/V2 (SEQ ID NO: 184), AE.A244 V1/V2tag (SEQ ID NO: 196), A.Q23V1/V2 (SEQ ID NO: 183), or A.Q23V1/V2tag (SEQ ID NO: 195).

5. The composition of claim 2 , wherein the polypeptide is AE.A244 V1/V2 (SEQ ID NO: 184).

6. The composition of claim 2 , wherein the polypeptide is AE.A244 V1/V2tag (SEQ ID NO: 196).

7. The composition of claim 2 , wherein the polypeptide is A.Q23V1/V2 (SEQ ID NO: 183).

8. The composition of claim 2 , wherein the polypeptide is A.Q23V1/V2tag (SEQ ID NO: 195).

9. The composition of claim 5 further comprising an adjuvant.

10. The composition according to claim 6 further comprising an adjuvant.

11. The composition according to claim 7 further comprising an adjuvant.

12. The composition according to claim 8 further comprising an adjuvant.

13. A method of inducing antibodies to the V1V2 region of HIV-1 env gp120 in a subject comprising administering to said subject the composition of claim 2 .

14. The method according to claim 13 wherein said subject is a human.

15. The method according to claim 13 further comprising administering an adjuvant.

16. The method according to claim 13 , wherein the composition is administered as prime.

17. A method of inducing antibodies to the V1V2 region of HIV-1 env gp120 in a subject comprising administering to said subject a composition comprising the polypeptide of claim 4 and a carrier.

18. The method according to claim 17 further comprising administering an adjuvant.

19. The method according to claim 17 , wherein the composition is administered as prime.

20. The method according to claim 17 , wherein the polypeptide consists essentially of peptide AE.A244 V1/V2 (SEQ ID NO: 184) or AE.A244 V1/V2tag (SEQ ID NO: 196).

Assignments (5)

CONFIRMATORY LICENSE Recorded Apr 24, 2018

From: DUKE UNIVERSITY

To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT

Reel/Frame 046009/0364 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 30, 2014

From: MICHAEL, NELSON

To: U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND

Reel/Frame 034597/0958 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2014

From: KIM, JEROME

To: U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND